Semaglutide Overview
Focused research with current evidence, limitations and jurisdictional context.
ExploreGLP-1 MEDICATIONS
GLP-1 Medications: Drugs, Brands, Uses and Evidence
GLP-1 and related incretin medicines are often discussed as one category, but important differences exist between active ingredients, brands, approved indications, evidence and regulatory status.
Video explainer
How GLP-1 Medications Work
Watch the GLP1Scientist explainer before moving into individual medicines, evidence and comparisons.
SEMAGLUTIDE RESEARCH
Explore the semaglutide evidence set
Start with the molecule overview, then move into focused research on weight loss, safety, cost and alternatives.
Semaglutide for Weight Loss
Focused research with current evidence, limitations and jurisdictional context.
ExploreSemaglutide Side Effects
Focused research with current evidence, limitations and jurisdictional context.
ExploreSemaglutide Cost
Focused research with current evidence, limitations and jurisdictional context.
ExploreSemaglutide Alternatives
Focused research with current evidence, limitations and jurisdictional context.
ExploreResearch brief
GLP-1 Medications: Drugs, Brands, Uses and Evidence
GLP-1 medicines are prescription therapies that act on the glucagon-like peptide-1 pathway, while some newer treatments combine GLP-1 activity with another incretin pathway. Medicines differ by active ingredient, brand, approved indication, studied population, safety information and jurisdiction. WHO currently discusses liraglutide, semaglutide and tirzepatide within its adult-obesity guidance. WHO, 2025.
Understanding the terminology
A useful starting point is to separate the active ingredient, the brand name and the therapeutic mechanism. Semaglutide and tirzepatide are different active ingredients. A manufacturer may market an ingredient under different brands for different indications or markets, while tirzepatide also has GIP activity in addition to GLP-1 receptor activity. Treating every incretin therapy as pharmacologically identical can therefore obscure meaningful differences.
Semaglutide and Wegovy
Wegovy contains semaglutide. EMA currently lists it for weight management in specified adults and adolescents under defined criteria, together with diet and physical activity. A semaglutide study result should not automatically be generalized to every formulation, dose, brand, population or jurisdiction. EMA: Wegovy.
Tirzepatide and Mounjaro
Mounjaro contains tirzepatide. EMA currently authorizes it in the EU for specified uses in type 2 diabetes and adult weight management under defined criteria. Tirzepatide therefore requires its own evidence and regulatory treatment rather than being treated as another brand of semaglutide. EMA: Mounjaro.
Why jurisdiction matters
Medicine names, approved uses, eligible populations, labeling, availability, reimbursement and access can differ across countries. GLP1Scientist therefore uses jurisdiction-specific regulatory sources whenever a page makes an approval or access claim.
How medication evidence should be read
Clinical trials report outcomes for defined populations under controlled protocols. Responsible comparisons consider the population, treatment duration, comparator, endpoint, regimen, discontinuation and adverse effects. Trial averages describe study results and should not be treated as individual predictions.
Broader research resources
Readers examining broader men's health and performance-support products can also explore evidence-oriented research at MalePerformanceSupplements.com and product-focused comparison material at MensPerformanceSupplements.com. These ecosystem resources do not replace regulator or clinical evidence for medication claims.
Sources and references
See also the research methodology, corrections policy, medical disclaimer and affiliate disclosure.
Frequently asked questions
Questions about this topic
What are the main GLP-1 medicines?
WHO obesity guidance discusses liraglutide, semaglutide and tirzepatide, while individual products and approved uses vary by jurisdiction.
Are Ozempic and Wegovy the same medicine?
They share semaglutide as an active ingredient, but brand, indication and product labeling must be checked separately.
Is tirzepatide the same as semaglutide?
No. Tirzepatide and semaglutide are different active ingredients with different pharmacological profiles.
Does a clinical-trial result predict how much weight an individual will lose?
No. Trial results describe outcomes in studied populations and should not be treated as personal forecasts.
About the author
Research direction by Dr. Rahul Dev
Dr. Rahul Dev is a data scientist, patent attorney, life-sciences researcher and global business strategist with more than 20 years of professional experience. His work spans biotechnology, pharmaceutical and patent intelligence, artificial intelligence, knowledge systems, technical research and international business strategy. He founded GLP1Scientist to organize complex GLP-1 evidence, regulatory information, market data, patent intelligence and commercial developments into a connected global research platform.
Dr. Rahul Dev is not a physician. GLP1Scientist does not provide diagnosis, prescribing, medical care or individualized treatment recommendations.
Continue your GLP-1 research
Use the connected research hubs to compare medicines, alternatives, safety questions and weight-loss evidence without losing the context behind the data.